Skip to main content
Back to Products
Retatrutide 30mg research peptide Australia

Retatrutide 30mg

30mg

Retatrutide 30mg offers an extended research supply of the groundbreaking triple agonist (GLP-1, GIP, glucagon) compound that is reshaping metabolic science. Retatrutide has shown greater efficacy in weight loss research than any previous generation of incretin-based peptides, with studies reporting double-digit percentage reductions in body mass. This larger 30mg vial is ideal for longer-duration protocols or comparative dose-response studies. Third-party HPLC tested. Lyophilised powder, requires reconstitution with bacteriostatic water.

A$210.00AUD
Volume Pricing
QtyPrice / unitSave / unit
1–2A$210.00-
3+A$199.50A$10.50
4.9· 7 reviews
Quantity
1

Crypto payments only , How to pay guide

Research Use Only: For laboratory research purposes only. Not for human or animal consumption.

Documentation

COA-backed

Source

Manufacturer COA

Shipping

Australia-wide

Payment

Crypto only

Australia-wide dispatch

Australia Post Express tracked · 1–2 business days

Research-grade · COA-verified

Third-party HPLC purity testing · manufacturer CoA

Crypto payment

BTC · LTC · XMR · researcher privacy by design

Batch & testing

Current batch
RETA30-2601-01
HPLC purity
99.79%
Test method
HPLC
Test date
7 January 2026
Source
Manufacturer Certificate of Analysis
Redacted manufacturer Certificate of Analysis, batch RETA30-2601-01

The current batch's manufacturer Certificate of Analysis, identifying details redacted to protect our supply chain.

RetaLABS Retatrutide 30mg is the largest-format lyophilised research vial of LY3437943, a triple GLP-1, GIP, and Glucagon receptor agonist developed by Eli Lilly. The 30mg format is the best-value option for Australian researchers running extended-duration cohorts: at the 4mg/week Phase 2 maintenance dose, a single 30mg vial supplies 7.5 weeks of research; at the 8mg/week cohort it covers approximately 3.75 weeks; at the peak 12mg/week dose it lasts 2.5 weeks. Per-milligram cost on the 30mg vial is the lowest in the range, and fewer reconstitution events across a protocol reduces handling overhead and exposure to freeze-thaw cycles.

Supplied as a white lyophilised powder. Shipped via Express Post Australia-wide in discrete, unmarked packaging, typically dispatched within 1–2 business days of confirmed crypto payment (BTC, LTC, or XMR).

Why Retatrutide Is Mechanistically Distinct

Retatrutide is the first triple receptor agonist in human clinical trials in the GLP-1 class. The compound simultaneously activates three receptors that have historically been engaged separately or in pairs:

  • GLP-1R (Glucagon-Like Peptide-1 Receptor). Drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety via hypothalamic and brainstem pathways. This is the receptor engaged by Semaglutide and the GLP-1 component of Tirzepatide.
  • GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor). Amplifies beta-cell insulin secretion through pathways distinct from GLP-1R, modulates adipose tissue lipid handling, and appears to reduce the GI adverse-event burden associated with isolated GLP-1R agonism. This is the second receptor engaged by Tirzepatide (the "twincretin" target).
  • GcgR (Glucagon Receptor). The third receptor, unique to Retatrutide among the three primary research-grade GLP-1 class peptides. GcgR agonism drives hepatic fatty acid oxidation and thermogenesis, adding an energy-expenditure mechanism on top of the appetite-suppression and insulin-secretion mechanisms of GLP-1R/GIPR.

For the full mechanism explainer including how GcgR's glucose-raising effect is offset by GLP-1R co-agonism, see the Glucagon Receptor Explained entity page. For the GLP-1 entity overview see GLP-1 Explained.

Phase 2 Trial Data, What Researchers Are Working From

The pivotal Phase 2 trial (Jastreboff et al., NEJM 2023, NCT04881760) enrolled 338 adults across six cohorts over 48 weeks. Top-line outcomes at the 48-week primary endpoint, by dose:

Dose cohort Mean weight loss Placebo-adjusted
Placebo2.1%-
1mg/week8.7%~6.6%
4mg/week (fast titration)17.3%~15.2%
8mg/week22.8%~20.7%
12mg/week24.2%~22.1%

Secondary endpoint magnitudes at the 12mg cohort: approximately 41% mean reduction in fasting insulin; approximately 43% mean reduction in triglycerides; approximately 18.5 cm mean reduction in waist circumference; meaningful reduction in liver fat fraction on MRI in the measured subset.

The 30mg vial best suits researchers running the full Phase 2 escalation schedule. The 12mg-cohort escalation consumes 2 + 2 + 2 + 2 + 4 + 4 + 4 + 4 + 8 + 8 + 8 + 8 + 10 + 10 + 10 + 10 = 96 mg over 16 weeks before reaching peak maintenance dose, meaning two 30mg vials cover the full escalation period, and subsequent maintenance can be planned around a 30mg-vial cadence (2.5 weeks of supply per vial at 12mg/week). Researchers running shorter cohorts at lower doses generally prefer the 20mg or 10mg formats.

For the full Phase 2 statistics including adverse event rates, discontinuation breakdown, and cohort-by-cohort numbers, see the Retatrutide Statistics 2026 data page.

Cross-Compound Comparison

Retatrutide research is most usefully contextualised against the two other compounds in the GLP-1 receptor agonist class with the strongest published trial data. The following table is cross-trial (drawn from separate studies with different populations, durations, and dose designs, not a head-to-head trial) so direct ranking requires caution:

Metric Semaglutide Tirzepatide Retatrutide
Receptor targetsGLP-1RGLP-1R + GIPRGLP-1R + GIPR + GcgR
Compound classSingleDual (twincretin)Triple agonist
DeveloperNovo NordiskEli LillyEli Lilly
Pivotal trialSTEP 1, 68 weeksSURMOUNT-1, 72 weeksPhase 2, 48 weeks
Highest dose2.4mg/week15mg/week12mg/week
Mean weight loss (highest dose)14.9%20.9%24.2%
Half-life~7 days~5 days~6 days
Phase 3 statusCompleteCompleteTRIUMPH ongoing

For full side-by-side comparisons see Retatrutide vs Tirzepatide and Retatrutide vs Semaglutide.

Reconstitution at a Glance

The most common research-protocol approach for a 30mg vial: add 3.0mL bacteriostatic water to produce a 10mg/mL working concentration. At this concentration, individual dose volumes on a standard U100 insulin syringe are:

Dose Volume at 10mg/mL U100 syringe units Doses per vial
2 mg0.20 mL20 units15
4 mg0.40 mL40 units7 (2mg remainder)
8 mg0.80 mL80 units3 (6mg remainder)
12 mg1.20 mL120 units (split injection)2 (6mg remainder)

At 12mg dose volumes (1.2 mL), researchers commonly split the injection across two sites at the same session for tolerability. Reconstitution technique: inject the bacteriostatic water slowly down the inner wall of the vial, swirl gently (do not shake), and store the reconstituted solution refrigerated at 2–8°C. The bacteriostatic water diluent contains 0.9% benzyl alcohol as a preservative, supporting multiple withdrawals from the same vial across an approximately 4-week stability window. For full protocol detail see the Peptide Reconstitution & Storage Guide and the reconstitution calculator.

Sourcing, Quality & Documentation

RetaLABS Retatrutide is supplied as research-grade, manufacturer-verified lyophilised peptide. Each batch is purity-tested by HPLC. Where a batch is published, its Certificate of Analysis appears on this page; full batch documentation is available on request, email support@retalabs.is with your order number.

All Retatrutide vials are supplied for laboratory research use only. Retatrutide is not approved as a therapeutic in Australia (TGA register confirmed); it has not completed Phase 3 trials in any jurisdiction. By placing an order you confirm the compound is acquired for research purposes and not for human consumption. For the regulatory framework see Retatrutide Legal Status in Australia.

Primary Research References

The core peer-reviewed publications underlying current Retatrutide research:

  • Jastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial." New England Journal of Medicine, 2023; 389:514-526. doi:10.1056/NEJMoa2301972. The pivotal Phase 2 dose-finding study. NCT04881760.
  • Coskun T et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." Cell Metabolism, 2022; 34:1234-1247. doi:10.1016/j.cmet.2022.07.013. Original receptor-binding characterisation and Phase 1 pharmacokinetic profile.
  • Rosenstock J et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet, 2023; 402:529-544. doi:10.1016/S0140-6736(23)01053-X. Phase 2 trial in adults with type 2 diabetes.
  • Sanyal AJ et al. "Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: a randomised, double-blind, placebo-controlled, phase 2a trial." Nature Medicine, 2024; 30:2037-2048. Phase 2a MASH/NAFLD trial; positions Retatrutide for the TRIUMPH-NAFLD Phase 3.
  • ClinicalTrials.gov registrations: Phase 2 trial NCT04881760; Phase 3 TRIUMPH-1 NCT05882045, TRIUMPH-2 NCT05882049, TRIUMPH-3 NCT05882077, TRIUMPH-4 NCT05989711, SYNERGY-OUTCOMES NCT06077864, TRIUMPH-NAFLD NCT06324877.

The RetaLABS Research Team's editorial and sourcing methodology is documented at the RetaLABS Research Team profile.

Related Research Reading

The full Retatrutide research cluster:

Customer Reviews

4.9 from 7 reviews
Kellie Marsh8 May 2026
Verified Buyer5 May 2026

Flawless experience, thanks!

Verified Buyer4 May 2026

Service was excellent

Aaron Nolan30 Apr 2026
Kyle S.28 Apr 2026
Brianna Stafford26 Apr 2026

Couldn't be happier

Verified Buyer25 Apr 2026

Product Specifications

Research-grade, manufacturer-verified

Lyophilised powder

~4.4 kDa

-20°C (lyophilised), 2-8°C (reconstituted)

Bacteriostatic water or sterile saline

39-residue triple agonist (GLP-1 / GIP / Glucagon) · Aib substitutions · C20 fatty-diacid acylation

Research Use Only: These products are intended for laboratory research use only and are not approved for human consumption. All purchases are subject to our terms of service and local regulations.

Frequently Asked Questions

Everything you need to know about Retatrutide 30mg

Research Guides

Retatrutide Molecular Profile: Formula, Weight, CAS Number, Sequence and Structure

8 min read

Retatrutide Australia 2026: Research Guide, Mechanism, Trial Data & Reconstitution

15 min read

Retatrutide 2026: Phase 3 Trials and What Researchers Should Know

17 min read

Retatrutide vs Tirzepatide: Triple vs Dual GLP-1 Agonism in Research

8 min read

Buying Research Peptides with Crypto in Australia: A Practical Guide

5 min read

Retatrutide Dosing Protocol: Phase 2 Trial Reference for Researchers

8 min read

GLP-1 and lean mass loss: what the clinical data actually shows: and why the receptor mechanism matters

16 min read

Why GLP-1 receptor agonists drive lean mass loss: the physiology behind the body composition data

11 min read

Drugs studied to preserve muscle on GLP-1s: bimagrumab, enobosarm, and the activin–myostatin approach

11 min read

Retatrutide Dosage Protocol Australia: Phase 2 Dosing Schedule & Escalation Guide

10 min read

Retatrutide Side Effects: Phase 2 Safety Data for Australian Researchers

8 min read

Retatrutide vs Semaglutide: Mechanism, Efficacy, and Research Comparison

8 min read

Retatrutide Cost Australia: Price Guide, Value Considerations & Sourcing

6 min read

Is Retatrutide Legal in Australia? TGA Status, Research Use & Sourcing

7 min read

Retatrutide vs Tirzepatide Australia: Triple vs Dual Agonist Research Comparison

8 min read

Retatrutide Statistics 2026: Trial Numbers, Dose-Cohort Data & Phase 3 Enrollment

11 min read

Retatrutide Research in Australia: 2026 Annual Report

14 min read

Retatrutide Research Papers: Primary Source Index 2026

8 min read

Retatrutide FAQ: 50 Research Questions Answered

18 min read

Retatrutide TRIUMPH-1 Results (2026): What the Phase 3 Data Showed

9 min read